COST-EFFECTIVENESS ANALYSIS OF IXEKIZUMAB VERSUS SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND CONCOMITANT MODERATE-TO-SEVERE PSORIASIS IN SPAIN

被引：1
|
作者：
Schweikert, B. [1 ]
Storck, C. T. [1 ]
Nunez, M. [2 ]
Dilla, T. [3 ]
Hartz, S. [4 ]
Sapin, C. [5 ]
机构：
[1] ICON, Munich, Germany
[2] Eli Lilly & Co, Alcobendas, Spain
[3] Lilly Spain, Madrid, Spain
[4] Eli Lilly & Co, Windlesham, Surrey, England
[5] Eli Lilly & Co, Neuilly Sur Seine, France
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.1902
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMU66
引用
收藏
页码：S319 / S319
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain
    Schweikert, Bernd
    Malmberg, Chiara
    Nunez, Mercedes
    Dilla, Tatiana
    Sapin, Christophe
    Hartz, Susanne
    BMJ OPEN, 2020, 10 (08):
  • [2] COST-EFFECTIVENESS ANALYSIS OF IXEKIZUMAB VERSUS SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND CONCOMITANT MODERATE-TO-SEVERE PSORIASIS IN THE UNITED KINGDOM
    Storck, C. T.
    Schweikert, B.
    Akerborg, O. P.
    Kumar, G.
    Nott, D. H.
    Kiri, S.
    Sapin, C.
    Hartz, S.
    VALUE IN HEALTH, 2018, 21 : S319 - S319
  • [3] Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
    Bernd Schweikert
    Chiara Malmberg
    Örjan Åkerborg
    Gayathri Kumar
    Debby Nott
    Sandeep Kiri
    Christophe Sapin
    Susanne Hartz
    PharmacoEconomics - Open, 2020, 4 : 635 - 648
  • [4] Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
    Schweikert, Bernd
    Malmberg, Chiara
    Akerborg, Orjan
    Kumar, Gayathri
    Nott, Debby
    Kiri, Sandeep
    Sapin, Christophe
    Hartz, Susanne
    PHARMACOECONOMICS-OPEN, 2020, 4 (04) : 635 - 648
  • [5] Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis
    Papp, Kim
    Gottlieb, Alice B.
    Shuler, Catherine L.
    Burge, Russel T.
    Cameron, Gregory
    Kerr, Lisa
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [6] Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment or moderate-to-severe psoriasis in the UK
    Johansson, Erin Colleen
    Hartz, Susanne
    Kiri, Sandeep Himatlal
    Kumar, Gayathri
    Svedbom, Axel
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (08) : 810 - 820
  • [7] Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate- to-severe plaque psoriasis in Spain
    Johansson, Erin
    Nunez, Mercedes
    Svedbom, Axel
    Dilla, Tatiana
    Hartz, Susanne
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 747 - 759
  • [8] Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective
    Igarashi, Atsuyuki
    Igarashi, Ataru
    Graham, Christopher N.
    Gilloteau, Isabelle
    Tani, Yumiko
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (01) : 7 - 15
  • [9] Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
    Schlueter, Max
    Finn, Elaine
    Diaz, Silvia
    Dilla, Tatiana
    Inciarte-Mundo, Jose
    Fakhouri, Walid
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 395 - 403
  • [10] Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis
    Vu, Trang T.
    Gooderham, Melinda
    Papp, Kim
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (11) : 1423 - 1433
12345